-
-
-
-
-
-
-
Takeda Pharmaceutical (TAK) Announces Publication of SOLSTICE Phase 3 Trial for LIVTENCITY in Post-Transplant Recipients With Cytomegalovirus Infection
-
-
-
-
-
-
-
Takeda (TAK) Subgroup Analysis from Phase 3 Clinical Trial Supports Efficacy of Maribavir Over Conventional Therapies in Transplant Recipients With Cytomegalovirus Infection
-
-
-
68,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

